Literature DB >> 3224817

Boundaries of telomere conversion in Trypanosoma brucei.

J M Kooter1, A J Winter, C de Oliveira, R Wagter, P Borst.   

Abstract

Active genes for variant-specific surface glycoproteins (VSGs) reside in telomeric expression sites and may be replaced by other VSG genes via telomere conversions. The availability of a complete map of expression site 221 in variant 221a made it possible to determine the boundaries of such conversions and the sequences that are involved. We have analysed five trypanosome populations that arose from variant 221a through replacement of the 221 gene by another VSG gene. In each of these relapsed populations the telomere conversion ends at a different position in the expression site. In the relapsed population, 221aR3, the boundary was found in the coding region of an expression-site-associated gene (ESAG). This ESAG-2 codes for a potential 368-aa protein of unknown function; it contains a N-terminal signal peptide for mediating transfer to the endoplasmic reticulum and six potential N-glycosylation sites. It shares these structural features with the ESAG-1 protein encoded in the same expression site. ESAG-2 is a member of a large gene family which includes non-functional genes. In 221aR3, the partial conversion of ESAG-2 by an ESAG-2-like sequence has disrupted the open reading frame. The two ESAG-2 sequences are similar (92% identity) suggesting that sequence homology between telomeres provides the opportunity for gene conversion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3224817     DOI: 10.1016/0378-1119(88)90372-1

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  9 in total

1.  Duplicative activation mechanisms of two trypanosome telomeric VSG genes with structurally simple 5' flanks.

Authors:  K R Matthews; P G Shiels; S V Graham; C Cowan; J D Barry
Journal:  Nucleic Acids Res       Date:  1990-12-25       Impact factor: 16.971

Review 2.  Microbial antigenic variation mediated by homologous DNA recombination.

Authors:  Cornelis Vink; Gloria Rudenko; H Steven Seifert
Journal:  FEMS Microbiol Rev       Date:  2012-01-17       Impact factor: 16.408

3.  VSG switching in Trypanosoma brucei: antigenic variation analysed using RNAi in the absence of immune selection.

Authors:  Niall Aitcheson; Suzanne Talbot; Jesse Shapiro; Katie Hughes; Carl Adkin; Thomas Butt; Karen Sheader; Gloria Rudenko
Journal:  Mol Microbiol       Date:  2005-09       Impact factor: 3.501

4.  A family of genes related to a new expression site-associated gene in Trypanosoma equiperdum.

Authors:  I C Florent; A Raibaud; H Eisen
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

5.  A random sequencing approach for the analysis of the Trypanosoma cruzi genome: general structure, large gene and repetitive DNA families, and gene discovery.

Authors:  F Agüero; R E Verdún; A C Frasch; D O Sánchez
Journal:  Genome Res       Date:  2000-12       Impact factor: 9.043

6.  TOPO3alpha influences antigenic variation by monitoring expression-site-associated VSG switching in Trypanosoma brucei.

Authors:  Hee-Sook Kim; George A M Cross
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

7.  A transferrin-binding protein of Trypanosoma brucei is encoded by one of the genes in the variant surface glycoprotein gene expression site.

Authors:  D Schell; R Evers; D Preis; K Ziegelbauer; H Kiefer; F Lottspeich; A W Cornelissen; P Overath
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

8.  Transferrin-binding protein complex is the receptor for transferrin uptake in Trypanosoma brucei.

Authors:  D Steverding; Y D Stierhof; H Fuchs; R Tauber; P Overath
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

9.  Trypanosoma brucei gambiense adaptation to different mammalian sera is associated with VSG expression site plasticity.

Authors:  Carlos Cordon-Obras; Jorge Cano; Dolores González-Pacanowska; Agustin Benito; Miguel Navarro; Jean-Mathieu Bart
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.